Congratulations to Erin Stephens who defended her B exam (thesis defense) on April 19, 2018! Her thesis focused on understanding the design principles of "ubiquibodies" - engineered chimeras that that selectively tag cellular proteins for destruction. The ubiquibody-based paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting "undruggable" as well as "druggable" elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets. Erin is now pursuing opportunities in the biotech/biopharma industry.